Key facts
- This page summarizes David A. Urbanek's Form 4 filing for Elanco Animal Health Inc (ELAN).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Mar 2023, 20:08.
David A. Urbanek - 01 Mar 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)
- Reporting relationship
- Executive Vice President, Manufacturing and Quality
- Issuer ticker
- ELAN
- Reported as of
- 01 Mar 2023
- Net transaction value
- -$43,593
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2023, 20:08:30 UTC
- Prior SEC filing
- 03 Mar 2022
- Next SEC filing
- 06 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Catherine S. Powell, as Attorney-in-Fact for David A. Urbanek
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David A. Urbanek filed Form 4 for Elanco Animal Health Inc (ELAN) on 03 Mar 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2022.
- Current net transaction value: -$43,593.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELAN
transaction
Common Stock
Tax liability
- Transaction value
- $32,913
- Shares
- -2,923
- Change %
- -3.2%
- Price
- $11.26
- Shares after
- 89,435
- Date
- 01 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
ELAN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +26,577
- Change %
- +30%
- Price
- $0.000000
- Shares after
- 116,012
- Date
- 01 Mar 2023
- Ownership
- Direct
- Footnotes
- F2
ELAN
transaction
Common Stock
Tax liability
- Transaction value
- $10,680
- Shares
- -970
- Change %
- -0.84%
- Price
- $11.01
- Shares after
- 114,383
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELAN
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +60,700
- Change %
- Price
- $0.000000
- Shares after
- 60,700
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,700
- Exercise price
- $11.26
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan.
Footnote F2
Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2023, one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.
Footnote F3
Balance reflects 659 fewer shares due to an error in the number of shares previously reported as forfeited in a prior Form 4.
Footnote F4
Grant of stock options vesting as follows: one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.
SEC remarks
Executive Vice President, Manufacturing and Quality